Lipids, blood pressure and bone metabolism after growth hormone therapy in elderly hemodialysis patients.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the context of low blood pressure and orthostatic hypotension in this randomized controlled trial publication.

The aim of this study is to elucidate the effects of GH-therapy on lipid profiles, blood pressure and bone metabolism.

Who Took Part

The abstract describes 7 patients taking part.

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

What Was Measured

The subject headings attached to it are Age Factors, Blood Pressure, Blood Pressure Determination, Bone Density, Human Growth Hormone, Kidney Failure, Chronic and Lipid Metabolism.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 7 patients in people with low blood pressure and orthostatic hypotension.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2003 (Journal of nephrology), a journal based in Italy.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, Low blood pressure and orthostatic hypotension research.